Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Common Equity (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Common Equity data on record, last reported at $480.5 million in Q1 2026.

  • On a quarterly basis, Common Equity rose 25.3% to $480.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $480.5 million, a 25.3% increase, with the full-year FY2025 number at $478.6 million, up 17.02% from a year prior.
  • Common Equity reached $480.5 million in Q1 2026 per OLMA's latest filing, roughly flat from $478.6 million in the prior quarter.
  • Over the last five years, Common Equity for OLMA hit a ceiling of $480.5 million in Q1 2026 and a floor of $161.6 million in Q2 2023.
  • A 5-year average of $285.2 million and a median of $253.9 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 33.99% in 2023, then surged 62.26% in 2025.
  • Tracing OLMA's Common Equity over 5 years: stood at $197.5 million in 2022, then grew by 28.52% to $253.9 million in 2023, then skyrocketed by 61.08% to $409.0 million in 2024, then increased by 17.02% to $478.6 million in 2025, then grew by 0.4% to $480.5 million in 2026.
  • Business Quant data shows Common Equity for OLMA at $480.5 million in Q1 2026, $478.6 million in Q4 2025, and $307.5 million in Q3 2025.